Physician profile
Donna E Tisch
NPI 1942468988
$1,592.15
in general payments reported to CMS, 2019-2025
28 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $62.89 · 2022: $414 · 2023: $269 · 2024: $300 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.16 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $217.82 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $147.84 | 2019-2025 | |
| Hologic Sales and Service, LLC | $84.65 | 2019-2025 | Omni Hysteroscope, Acessa Provu System |
| Exact Sciences Corporation | $81.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Coopersurgical, INC. | $78.66 | 2019-2025 | Paragard T 380a, Cook |
| Exeltis, USA INC. | $78.34 | 2019-2025 | Slynd |
| Pfizer INC. | $66.54 | 2022-2023 | |
| Myovant Sciences INC. | $62.52 | 2022 | |
| Biogen, INC. | $59.61 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $50.98 | 2022 | |
| Mayne Pharma Commercial LLC | $45.33 | 2023-2024 | |
| Amag Pharmaceuticals, INC. | $41.78 | 2019 | |
| Shield Therapeutics INC | $34.20 | 2022 | |
| Duchesnay USA Incorporated | $26.94 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.77 | 2022 | |
| Minerva Surgical, INC | $23.22 | 2019 | |
| Mylan Pharmaceuticals INC. | $23.02 | 2022 | |
| Convatec INC. | $21.38 | 2019 | |
| Axsome Therapeutics, INC. | $21.02 | 2024 | Auvelity |
| Millicent US INC | $19.29 | 2025 | Femlyv |
| Smith+Nephew, INC. | $16.94 | 2019 | |
| Avion Pharmaceuticals | $15.89 | 2023 | Balcoltra |
| Dexcom, INC. | $15.19 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $14.26 | 2023 | Contrave |
| Pacira Pharmaceuticals Incorporated | $12.64 | 2022 | |
| Meditrina | $12.21 | 2023 | |
| Organon LLC | $10.12 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Tisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.